Irradiation stent with 125I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
Gao‐Jun Teng(Yangzhou University), Wei‐Fu Lv(Anhui Medical University), Ligong Lu(Tongji University), Dong Lu(University of Science and Technology of China), Po Song Yang(Harbin Medical University), Junhui Sun(First Affiliated Hospital Zhejiang University), Jiansong Ji(Lishui University), Wan Yee Lau(Chinese University of Hong Kong), Guangshao Cao(Henan University), Wujie Wang(Second Hospital of Shandong University), Hai‐Dong Zhu(Zhongda Hospital Southeast University), Guang-Yu Zhu(Zhongda Hospital Southeast University), Sheng-Qun Chen(Pancreas Centre (Canada)), Haibo Shao(First Hospital of China Medical University), Jin-He Guo(Zhongda Hospital Southeast University), Weidong Wang(First Affiliated Hospital Zhejiang University), Rui Li(Wannan Medical College), Hai-Liang Li(Zhengzhou University), Fujun Zhang(Sun Yat-sen University), Weixin Ren(Xinjiang Medical University), Jie Min(Union Hospital), Yang Zhao(Nanjing Medical University), Kun Gao(Capital Medical University), Guowen Yin(Jiangsu Cancer Hospital), Yuliang Li(Second Hospital of Shandong University), Fazong Wu(Wenzhou Medical University)
Cited by 29
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
|Signal Transduction and Targeted Therapy|2023|295
The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
|Cell Communication and Signaling|2020|232